Johnson Pharmacare reports FY26 loss, audit flags Ind AS gaps
Johnson Pharmacare reported a net loss of ₹5,573.39 lakh for FY26, a sharp increase from the previous year's loss of ₹58.38 lakh, with total expenses reaching ₹4,304.49 lakh. The statutory auditor issued a disclaimer of opinion due to non-compliance with Ind AS and the lack of an audit trail in accounting software. Significant concerns were raised regarding the company's internal controls, loan terms, and its ability to meet financial obligations.
*this image is generated using AI for illustrative purposes only.
Johnson Pharmacare reported a widened net loss of ₹5,573.39 lakh for the financial year ended March 31, 2026, significantly higher than the loss of ₹58.38 lakh recorded in the previous year. The company’s total income for the year stood at ₹158.10 lakh, while total expenses surged to ₹4,304.49 lakh, driven largely by other expenses amounting to ₹4,276.48 lakh. The basic and diluted earnings per share (EPS) for the year were reported at negative ₹1.01.
The statutory auditor, VRSK & Associates, issued a disclaimer of opinion on the standalone financial statements, stating they may not give a true and fair view due to the non-provision of interest on loans and non-compliance with Ind AS prescribed under Section 133 of the Companies Act, 2013. The auditor noted that the company should have prepared financial statements in compliance with Ind AS, which may significantly affect the reported figures.
Audit Qualifications and Internal Controls
The audit report highlighted significant deficiencies in the company's internal financial controls. Specifically, the company did not maintain accounting software with a feature to record an audit trail for every transaction, including edit logs with dates, nor did it ensure the audit trail could not be disabled. This failure violates the proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014.
Furthermore, the auditor identified key audit matters concerning inter-corporate deposits and the fair valuation of unquoted investments. The company had a borrowed loan balance of ₹2,140.04 lakh as of March 31, 2026. The auditor noted that the terms of these loans, including repayment schedules and interest rates, were not clearly defined, raising significant risks regarding their conversion to equity capital.
Financial Position and Cash Flows
The company’s balance sheet as of March 31, 2026, showed total assets of ₹2,203.11 lakh, a sharp decline from ₹5,792.59 lakh in the previous year. Non-current investments decreased to ₹1,972.50 lakh from ₹4,229.16 lakh, while borrowings spiked to ₹2,140.19 lakh from ₹60.54 lakh. The net worth of the company stood at ₹43.52 lakh, down from ₹5,616.91 lakh in the prior year.
Cash flow analysis revealed a net decrease in cash and cash equivalents of ₹4.59 lakh during the quarter ended March 31, 2026. The company generated ₹5,783.16 lakh from investing activities, primarily due to an increase in investments, but utilized ₹5,745.54 lakh in operating activities. Financing activities saw a net outflow of ₹42.20 lakh, mainly due to the repayment of long-term borrowings.
Regulatory and Governance Issues
The auditor expressed serious doubts about the company’s ability to meet its liabilities as they fall due within one year from the balance sheet date. Additionally, the report noted that the company is required to be registered with the Reserve Bank of India under Section 45-IA of the RBI Act, 1934, as it extends loans and earns income mainly from interest. However, the company does not meet the criteria for a Core Investment Company.
| Financial Metric (in ₹ Lakh) | FY26 | FY25 |
|---|---|---|
| Total Income | 158.10 | (33.34) |
| Total Expenses | 4,304.49 | 7.88 |
| Net Profit/(Loss) | (5,573.39) | (58.38) |
| Earnings Per Share (Basic) | (1.01) | (0.01) |
| Total Assets | 2,203.11 | 5,792.59 |
| Net Worth | 43.52 | 5,616.91 |
The board approved the audited financial results at a meeting held on May 27, 2026. The filing was submitted to the stock exchanges on June 19, 2026.
Historical Stock Returns for Johnson Pharmacare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | 0.0% | -7.27% | -13.56% | -40.70% | +112.50% |
What specific remediation measures will management implement to address the significant internal control deficiencies and ensure compliance with Ind AS standards?
Given the auditor's doubts about meeting liabilities within one year, what immediate liquidity strategies or capital raising plans does the company intend to pursue?
How does the company plan to resolve the undefined terms of the ₹2,140.04 lakh loans, and what is the likelihood of these converting to equity capital?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
